Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | STAT3 | P40763 | 1/20 | 1.00 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.76 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.76 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.76 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.76 |
| ▸ | GAA | P10253 | 1/20 | 0.76 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.76 |
| ▸ | TSHR | P16473 | 1/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.76 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.76 |
| ▸ | CBR1 | P16152 | 1/20 | 0.69 |
| ▸ | F13A1 | P00488 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31122092 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2HPGDNR1I2ESR1 | |
| SCHEMBL19084151 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2HPGDNR1I2ESR1 | |
| SCHEMBL342587 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2HPGDNR1I2ESR1 | |
| SCHEMBL342992 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2HPGDNR1I2ESR1 | |
| SCHEMBL588697 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2HPGDNR1I2ESR1 | |
| SCHEMBL588698 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2HPGDNR1I2ESR1 | |
| SCHEMBL588699 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2HPGDNR1I2ESR1 | |
| SCHEMBL109175 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2HPGDNR1I2ESR1 | |
| SCHEMBL22713161 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2HPGDNR1I2ESR1 | |
| SCHEMBL29929287 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2HPGDNR1I2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11998028-B2 | Polypeptide for hydrolytic cleavage of zearalenone and/or zearalenone derivatives, isolated polynucleotide thereof as well as a polypeptide containing an additive, use of same as well as a process | ERBER AKTIENGESELLSCHAFT (AT) | 2024-06-04 | — | — | US | claimed |
| US-11998027-B2 | Polypeptide for hydrolytic cleavage of zearalenone and/or zearalenone derivatives, isolated polynucleotide thereof as well as a polypeptide containing an additive, use of same as well as a process | ERBER AKTIENGESELLSCHAFT (AT) | 2024-06-04 | — | — | US | claimed |
| US-20220202045-A1 | POLYPEPTIDE FOR HYDROLYTIC CLEAVAGE OF ZEARALENONE AND/OR ZEARALENONE DERIVATIVES, ISOLATED POLYNUCLEOTIDE THEREOF AS WELL AS A POLYPEPTIDE CONTAINING AN ADDITIVE, USE OF SAME AS WELL AS A PROCESS | ERBER AKTIENGESELLSCHAFT (AT) | 2022-06-30 | — | — | US | claimed |
| US-11324235-B2 | Polypeptide for hydrolytic cleavage of zearalenone and/or zearalenone derivatives, isolated polynucleotide thereof as well as a polypeptide containing an additive, use of same as well as a process | ERBER AKTIENGSELLSCHAFT (AT) | 2022-05-10 | — | — | US | claimed |
| US-20200375218-A1 | POLYPEPTIDE FOR HYDROLYTIC CLEAVAGE OF ZEARALENONE AND/OR ZEARALENONE DERIVATIVES, ISOLATED POLYNUCLEOTIDE THEREOF AS WELL AS A POLYPEPTIDE CONTAINING AN ADDITIVE, USE OF SAME AS WELL AS A PROCESS | ERBER AKTIENGESELLSCHAFT (AT) | 2020-12-03 | — | — | US | claimed |
| US-10779556-B2 | Polypeptide for hydrolytic cleavage of zearalenone and/or zearalenone derivatives, isolated polynucleotide thereof as well as a polypeptide containing an additive, use of same as well as a process | ERBER AKTIENGESELLSCHAFT (AT) | 2020-09-22 | — | — | US | claimed |
| US-20190124948-A1 | POLYPEPTIDE FOR HYDROLYTIC CLEAVAGE OF ZEARALENONE AND/OR ZEARALENONE DERIVATIVES, ISOLATED POLYNUCLEOTIDE THEREOF AS WELL AS A POLYPEPTIDE CONTAINING AN ADDITIVE, USE OF SAME AS WELL AS A PROCESS | ERBER AKTIENGESELLSCHAFT (AT) | 2019-05-02 | — | — | US | claimed |
| US-10149489-B2 | Polypeptide for hydrolytic cleavage of zearalenone and/or zearalenone derivatives, isolated polynucleotide thereof as well as a polypeptide containing an additive, use of same as well as a process | ERBER AKTIENGESELLSCHAFT (AT) | 2018-12-11 | — | — | US | claimed |
| US-10076125-B2 | Polypeptide for hydrolytic cleavage of zearalenone and/or zearalenone derivatives, isolated polynucleotide thereof as well as a polypeptide containing an additive, use of same as well as a process | ERBER AKTIENGESELLSCHAFT (AT) | 2018-09-18 | — | — | US | claimed |
| US-20260139235-A1 | MEANS AND METHODS FOR CLEAVAGE OF ZEARALENONE | DSM Austria GmbH (AT) | 2026-05-21 | — | — | US | disclosed |
| US-12371681-B2 | Means and methods for cleavage of zearalenone | DSM Austria GmbH (AT) | 2025-07-29 | — | — | US | disclosed |
| EP-3891306-B1 | BIOMARKER FOR DETECTING ZEARALENONE EFFECT | DSM Austria GmbH (AT) | 2025-02-26 | — | — | EP | disclosed |
| US-11998027-B2 | Polypeptide for hydrolytic cleavage of zearalenone and/or zearalenone derivatives, isolated polynucleotide thereof as well as a polypeptide containing an additive, use of same as well as a process | ERBER AKTIENGESELLSCHAFT (AT) | 2024-06-04 | — | — | US | disclosed |
| US-11998028-B2 | Polypeptide for hydrolytic cleavage of zearalenone and/or zearalenone derivatives, isolated polynucleotide thereof as well as a polypeptide containing an additive, use of same as well as a process | ERBER AKTIENGESELLSCHAFT (AT) | 2024-06-04 | — | — | US | disclosed |
| US-10076125-B2 | Polypeptide for hydrolytic cleavage of zearalenone and/or zearalenone derivatives, isolated polynucleotide thereof as well as a polypeptide containing an additive, use of same as well as a process | ERBER AKTIENGESELLSCHAFT (AT) | 2018-09-18 | — | — | US | disclosed |
| US-20160345606-A1 | POLYPEPTIDE FOR HYDROLYTIC CLEAVAGE OF ZEARALENONE AND/OR ZEARALENONE DERIVATIVES, ISOLATED POLYNUCLEOTIDE THEREOF AS WELL AS A POLYPEPTIDE CONTAINING AN ADDITIVE, USE OF SAME AS WELL AS A PROCESS | ERBER AKTIENGESELLSCHAFT (AT) | 2016-12-01 | — | — | US | disclosed |
| US-20160319258-A1 | POLYPEPTIDE FOR HYDROLYTIC CLEAVAGE OF ZEARALENONE AND/OR ZEARALENONE DERIVATIVES, ISOLATED POLYNUCLEOTIDE THEREOF AS WELL AS A POLYPEPTIDE CONTAINING AN ADDITIVE, USE OF SAME AS WELL AS A PROCESS | ERBER AKTIENGESELLSCHAFT (AT) | 2016-11-03 | — | — | US | disclosed |
| EP-2417118-B1 | A PROCESS FOR MANUFACTURING ZERANOL | INTERVET INT BV (NL) | 2016-01-27 | — | — | EP | disclosed |
| US-8674120-B2 | Process for manufacturing zeranol | INTERVET INTERNATIONAL B.V. (NL) | 2014-03-18 | — | — | US | disclosed |
| US-20120016137-A1 | PROCESS FOR MANUFACTURING ZERANOL | INTERVET INTERNATIONAL B.V. (NL) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371681-B2 | Means and methods for cleavage of zearalenone | GUSB, GGH, HDHD5 | LMNA 1087/4885SMN1; SMN2 3936/4885HPGD 544/4885 |
| US-20260139235-A1 | MEANS AND METHODS FOR CLEAVAGE OF ZEARALENONE | HDHD5, GGH, IDUA | LMNA 606/4885SMN1; SMN2 3454/4885HPGD 1521/4885 |
| US-20120016137-A1 | PROCESS FOR MANUFACTURING ZERANOL | CYP51A1, ZDHHC9, ERG28 | LMNA 3165/4885SMN1; SMN2 1549/4885HPGD 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.